167 related articles for article (PubMed ID: 25584235)
1. Persistent monotypic plasma cells with absence of neoplastic B cell component in a treated case of waldenström macroglobulinemia: a sign of residual disease?
Gajendra S; Sachdev R; Jha B; Goel S; Sahni T
J Clin Diagn Res; 2014 Nov; 8(11):FD12-3. PubMed ID: 25584235
[TBL] [Abstract][Full Text] [Related]
2. Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.
Barakat FH; Medeiros LJ; Wei EX; Konoplev S; Lin P; Jorgensen JL
Am J Clin Pathol; 2011 Mar; 135(3):365-73. PubMed ID: 21350089
[TBL] [Abstract][Full Text] [Related]
3. Waldenström macroglobulinemia: a review of the entity and its differential diagnosis.
Shaheen SP; Talwalkar SS; Lin P; Medeiros LJ
Adv Anat Pathol; 2012 Jan; 19(1):11-27. PubMed ID: 22156831
[TBL] [Abstract][Full Text] [Related]
4. A Rare Case of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma with Light Chain Discrepancy between B Lymphocyte Population and Serum Paraprotein.
Kim HJ; Hur M; Kim H; Moon HW; Yun YM; Kim SY; Lee MH
Ann Clin Lab Sci; 2015; 45(5):593-7. PubMed ID: 26586715
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Konoplev S; Medeiros LJ; Bueso-Ramos CE; Jorgensen JL; Lin P
Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
[TBL] [Abstract][Full Text] [Related]
7. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.
Hunter ZR; Branagan AR; Manning R; Patterson CJ; Santos DD; Tournilhac O; Dorfman DM; Treon SP
Clin Lymphoma; 2005 Mar; 5(4):246-9. PubMed ID: 15794857
[TBL] [Abstract][Full Text] [Related]
8. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
Remstein ED; Hanson CA; Kyle RA; Hodnefield JM; Kurtin PJ
Semin Oncol; 2003 Apr; 30(2):182-6. PubMed ID: 12720133
[TBL] [Abstract][Full Text] [Related]
9. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
10. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with Hodgkin disease. A report of two cases.
Rosales CM; Lin P; Mansoor A; Bueso-Ramos C; Medeiros LJ
Am J Clin Pathol; 2001 Jul; 116(1):34-40. PubMed ID: 11447749
[TBL] [Abstract][Full Text] [Related]
11. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
12. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
13. Role of plasma cells in Waldenström macroglobulinaemia.
El-Ayoubi A; Wang JQ; Hein N; Talaulikar D
Pathology; 2017 Jun; 49(4):337-345. PubMed ID: 28483372
[TBL] [Abstract][Full Text] [Related]
14. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
Lin P; Medeiros LJ
Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
Kyle RA; Ansell SM; Kapoor P
Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
[TBL] [Abstract][Full Text] [Related]
16. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
[TBL] [Abstract][Full Text] [Related]
17. [Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].
Liang DN; Li GD; Dai L; Huang J; Wang WY; Feng WH; Li FY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):728-32. PubMed ID: 20079010
[TBL] [Abstract][Full Text] [Related]
18. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
Berger F; Traverse-Glehen A; Felman P; Callet-Bauchu E; Baseggio L; Gazzo S; Thieblemont C; Ffrench M; Magaud JP; Salles G; Coiffer B
Clin Lymphoma; 2005 Mar; 5(4):220-4. PubMed ID: 15794852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
